BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 3132043)

  • 21. Effect of oral contraception on water-suppressed proton NMR spectra of plasma.
    Carlier PG; Vaesen F; Gilles RG; Fradin EA; Rorive GL
    Magn Reson Med; 1991 Jan; 17(1):269-73. PubMed ID: 1648654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
    Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation.
    Bostofte E; Hemmingsen L; Møller KJ; Serup J; Weber T
    Acta Endocrinol (Copenh); 1978 Apr; 87(4):855-64. PubMed ID: 347855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
    Wynn V; Niththyananthan R
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma lipids and lipoprotein lipase activating property in women on three different combinations of estrogens and progestins.
    Mendoza SG; Kashyap ML; Echeverria Y; Zerpa A
    Biochem Med; 1981 Jun; 25(3):283-7. PubMed ID: 7271764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
    LaRosa JC
    Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative studies of the ethynyl estrogens used in oral contraceptives. VI. Effects with and without progestational agents on carbohydrate metabolism in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; De La Pena A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Aug; 30(2):146-53. PubMed ID: 98357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some observations on the changes in capillary resistance in oral contraceptive users.
    Zaki K; Younis MN; Razek SA; Mekkawi TE; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):145-51. PubMed ID: 12256025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk.
    LaRosa JC
    Int J Fertil; 1989; 34 Suppl():71-84. PubMed ID: 2576264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):725-31. PubMed ID: 7065054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
    Godsland IF
    Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study.
    Greenlund KJ; Webber LS; Srinivasan S; Wattigney W; Johnson C; Berenson GS
    Ann Epidemiol; 1997 Nov; 7(8):561-7. PubMed ID: 9408552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of the metabolic effects of injectable and oral contraceptives.
    Liew DF; Ng CS; Heng SH; Ratnam SS
    Contraception; 1986 Apr; 33(4):385-94. PubMed ID: 2942334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of progestins on high-density lipoproteins.
    Bye P
    Am J Obstet Gynecol; 1983 Jun; 146(3):347-8. PubMed ID: 6859154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver function tests in patients on oral progestogens.
    Engineer AD; Gupta V; Tandon P
    J Obstet Gynaecol India; 1968 Apr; 18(2):598-605. PubMed ID: 12331828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.